Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Madrigal Pharmaceuticals, Inc. has granted an equity award to Rita Thakkar, the new Chief Accounting Officer, as part of its 2025 Inducement Plan [1][2] - The equity award includes 2,398 time-based restricted stock units and options to purchase 1,826 shares of common stock, with an exercise price of $495.88 per share [2] - Madrigal focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its medication Rezdiffra being the first approved treatment for MASH with moderate to advanced fibrosis [3] Group 1 - The equity award was approved by Madrigal's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) [1] - Options vesting schedule includes 25% on the first anniversary and 6.25% quarterly thereafter, while restricted stock units vest in four equal installments over four years [2] - Rezdiffra is a once-daily, oral, liver-directed THR-β agonist targeting key causes of MASH, with ongoing trials for compensated MASH cirrhosis [3]